OWD
NVS icon

Osborn Williams & Donohoe’s Novartis NVS Stock Holding History

Osborn Williams & Donohoe’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$4.68M Sell
56,780
-2,586
-4% -$231K 0.61% 50
2019
Q4 		$5.62M Sell
59,366
-2,200
-4% -$197K 0.56% 54
2019
Q3 		$5.35M Buy
61,566
+1,150
+2% +$103K 0.54% 53
2019
Q2 		$5.52M Sell
60,416
-9,417
-13% -$797K 0.57% 49
2019
Q1 		$5.12M Buy
69,833
+20,824
+42% +$1.67M 0.53% 55
2018
Q4 		$3.77M Sell
49,009
-7,057
-13% -$549K 0.67% 46
2018
Q3 		$4.33M Sell
56,066
-753
-1% -$55.7K 0.67% 46
2018
Q2 		$3.85M Sell
56,819
-139
-0.2% -$9.59K 0.65% 46
2018
Q1 		$4.13M Buy
56,958
+16
+0% +$1.22K 0.71% 45
2017
Q4 		$4.28M Sell
56,942
-2,926
-5% -$221K 0.73% 43
2017
Q3 		$4.61M Sell
59,868
-1,194
-2% -$90.2K 0.83% 36
2017
Q2 		$4.57M Sell
61,062
-5,542
-8% -$393K 0.83% 36
2017
Q1 		$4.43M Sell
66,604
-2,017
-3% -$134K 0.8% 38
2016
Q4 		$4.48M Sell
68,621
-2,770
-4% -$180K 0.84% 36
2016
Q3 		$5.05M Sell
71,391
-3,151
-4% -$230K 0.97% 32
2016
Q2 		$5.51M Sell
74,542
-1,294
-2% -$89.4K 1.07% 32
2016
Q1 		$4.92M Sell
75,836
-4,541
-6% -$309K 0.99% 34
2015
Q4 		$6.2M Buy
80,377
+1,847
+2% +$147K 1.28% 27
2015
Q3 		$6.42M Hold
78,530
– – 1.39% 21
2015
Q2 		$7.16M Sell
78,530
-2,451
-3% -$225K 1.44% 21
2015
Q1 		$7.16M Sell
80,981
-737
-0.9% -$65.4K 1.39% 20
2014
Q4 		$6.79M Buy
81,718
+737
+0.9% +$61.1K 1.33% 24
2014
Q3 		$6.83M Sell
80,981
-326
-0.4% -$26.4K 1.42% 18
2014
Q2 		$6.52M Sell
81,307
-95
-0.1% -$7.47K 1.35% 18
2014
Q1 		$6.2M Sell
81,402
-245
-0.3% -$17.9K 1.37% 20
2013
Q4 		$5.88M Sell
81,647
-725
-0.9% -$50.4K 1.32% 20
2013
Q3 		$5.66M Buy
82,372
+396
+0.5% +$26.2K 1.38% 17
2013
Q2 		$5.19M Buy
+81,976
New +$5.33M 1.35% 18

Other funds holding NVS

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Mawer Investment Management
Mawer Investment Management Calgary, Alberta, Canada $14.7B AUM 12.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Osborn Williams & Donohoe's NVS Position: Q1 2020 in Review

Osborn Williams & Donohoe reduced its Novartis (NVS) stake by 4.4% in Q1 2020, selling an estimated $231K and leaving 56,780 shares worth $4.68M. The position accounts for 0.61% of the portfolio, ranked #50.

Osborn Williams & Donohoe first reported a position in NVS in Q2 2013 and has held it in 28 quarters since. The position peaked at $7.16M in Q2 2015. 1,132 funds tracked by Wall St. Rank hold NVS as of Q1 2020.

  • Osborn Williams & Donohoe held 56,780 shares of Novartis worth $4.68M as of Q1 2020.
  • Osborn Williams & Donohoe sold 2,586 Novartis shares in Q1 2020, an estimated $231K.
  • Novartis made up 0.61% of Osborn Williams & Donohoe's portfolio in Q1 2020, its #50 holding.
  • Osborn Williams & Donohoe first reported a position in Novartis in Q2 2013 and has held it in 28 quarters since.
  • Osborn Williams & Donohoe's Novartis position peaked at $7.16M in Q2 2015.
  • 1,132 funds tracked by Wall St. Rank held Novartis as of Q1 2020.

Based on Osborn Williams & Donohoe's 13F filing for Q1 2020, filed 4 May 2020.